Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-An oral, direct and selective factor Xa inhibitor

Journal of Thrombosis and Thrombolysis

Volumn 32, Issue 2, 2011, Pages 183-187

  Becker, Richard C ^a   Yang, Hongqiu ^a   Barrett, Yuchen ^b   Mohan, Puneet ^b   Wang, Jessie ^b   Wallentin, Lars ^c   Alexander, John H ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acute coronary syndrome; Ant Xa activity; Apixaban

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; FONDAPARINUX; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; ASSAY; BLOOD SAMPLING; CHROMOGENIC ASSAY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; FACTOR XA; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES;

EID: 80052502475     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-011-0591-8     Document Type: Article

References (5)

1. Alexander JH, Becker RC et al (2009) Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation 119(22):2877-2885
2. Barrett YC, Wang Z et al (2010) Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost 104(6):1263-1271
3. Becker RC, Alexander JH et al (2010) Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. Thromb Haemost 104(5): 976-983
4. Jiang X, Crain EJ et al (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101(4):780-782
5. Samama MM, Martinoli JL et al (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815-825